Evidence map›Paper›PMID 25052724›Full record

Trial reportJournal of clinical hypertension (Greenwich, Conn.)2014

Effects of spironolactone on dialysis patients with refractory hypertension: a randomized controlled study.

Xiaoying Ni, Jisheng Zhang, Ping Zhang, Fuquan Wu, Min Xia, Guanghui Ying, Jianghua Chen

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical hypertension (Greenwich, Conn.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05688579 (Effect of Mineralcorticoid Recept Antagonist on Cardiovascular Disease in Patients With Hypertension and Hyperaldosteronemia：A Multicenter Randomized Controlled Study), which is not on this map. Cited by 31 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 9 pooled it
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05688579 phase4enrolling by invitationnot on this mapstarted 2023, after this paper: background citation

Effect of Mineralcorticoid Recept Antagonist on Cardiovascular Disease in Patients With Hypertension and Hyperaldosteronemia：A Multicenter Randomized Controlled Study

TypeinterventionalSponsorNanfang LiRan2023 to 2026Enrolled8,000ConditionsHypertension, HyperaldosteronaemiaArmsMineralocorticoid Receptor Antagonists(MRAs), Blank control
3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 9 syntheses or guidelines pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Mineralocorticoid Receptor Antagonists in Dialysis.American journal of nephrology · 2026
    Review
  15. Review
  16. Review
  17. Mineralocorticoid receptor antagonism attenuates arteriovenous fistula stenosis by modulating the phenotype of vascular smooth muscle cells.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Xiaoying NiDepartment of Nephrology, People's Hospital of Yinzhou, College of Medicine, Ningbo University, Ningbo, China.
Jisheng Zhang
Ping Zhang
Fuquan Wu
Min Xia
Guanghui Ying
Jianghua Chen
Zhejiang University · CNFirst Affiliated Hospital Zhejiang University · CNNingbo University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The purpose of this study was to evaluate the effects of spironolactone on dialysis patients with refractory hypertension and possible adverse effects. This was a 12-week prospective, randomized, double-blind trial of 82 patients randomly assigned to 12-week treatment with 25 mg/d spironolactone or placebo as add-on therapy. Visits were scheduled at the start of treatment and after 12 weeks. Measurements of 24-hour ambulatory blood pressure (BP) monitoring and morning BP were performed. After 12 weeks, spironolactone significantly improved refractory hypertension. Average placebo-corrected morning BP was reduced by 16.7/7.6 mm Hg. Mean 24-hour ambulatory BP was reduced by 10.9/5.8 mm Hg. In contrast, serum aldosterone levels in the spironolactone group slightly increased and serum potassium levels insignificantly increased. This study has demonstrated that spironolactone (50 mg) safely and effectively reduces BP in patients with refractory hypertension undergoing dialysis.

Indexed as

Renal DialysisAdultAgedAldosteroneBlood PressureBlood Pressure Monitoring, AmbulatoryDiureticsDose-Response Relationship, DrugDouble-Blind MethodFemaleHumansHypertensionMaleMiddle AgedPotassiumProspective StudiesAldosteroneDiureticsPotassiumSpironolactone

Identifiers

PMID25052724
PMCPMC8031582
OpenAlexW2065130807

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.